Trial Profile
Prospective observational study investigating the efficacy and tolerability of switching from bosentan to macitentan in patients with pulmonary arterial hypertension due to congenital heart disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Macitentan (Primary) ; Bosentan
- Indications Pulmonary arterial hypertension
- Focus Biomarker; Therapeutic Use
- 21 Oct 2015 New trial record
- 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology.